Once a Takeover Candidate, Vertex Is Now Looking for DealsBy
CEO says cystic fibrosis success justifies stand-alone company
Biotech firm would consider potential gene therapy, RNA deals
Vertex Pharmaceuticals Inc. has ranked high on investors’ lists of likely biotech acquisition targets. Now that the drugmaker is on the path to profit, it’s the one ready to go shopping.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.